Evidence map›Paper›PMID 42126782›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer.

Miharu Kano, Kanae Taruno, Mayuko Inuzuka, Reiko Makino, Mieko Takeuchi, Misato Suzuki, Kumiko Kida, Junko Takei, Aiko Nagayama, Tetsu Hayashida and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miharu KanoDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Kanae TarunoDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. ktaruno@med.showa-u.ac.jp.ORCID http://orcid.org/0000-0002-7754-1548
Mayuko InuzukaDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Reiko MakinoDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Mieko TakeuchiDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Misato SuzukiCenter for Medical Genetics, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Kumiko KidaDepartment of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi- cho, Chuo-ku, Tokyo, 104-8560, Japan.
Junko TakeiDepartment of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi- cho, Chuo-ku, Tokyo, 104-8560, Japan.
Aiko NagayamaDepartment of Breast Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Tetsu HayashidaDepartment of Breast Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Yurie HaruyamaBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Takayuki UenoBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Chie WatanabeDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Yasuyuki KojimaDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Rumi SasaiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan.
Mikiko EndoLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan.
Seigo NakamuraDivision of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, BRCA genetic testing for the diagnosis of hereditary breast and ovarian cancer is covered by medical insurance. However, other breast cancer (BC) susceptibility genes are rarely examined in these patients, primarily because medical insurance does not cover testing for these genes.

methodsA multigene panel testing (MGPT) was conducted on patients with BC who met the clinical criteria for BRCA genetic testing.

resultsOf the 494 patients, 45 germline pathogenic variants (GPVs) were identified (9.11%). The BRCA genetic testing criteria items with GPV detection rates > 10% were as follows: "diagnosed at age ≤ 45 years," "diagnosed with triple-negative breast cancer (TNBC) at age ≤ 60 years" and "≥1 close blood relative within the third degree on the same side of the family with breast, ovarian, or pancreas cancer."

conclusions. MGPT can identify GPVs in genetically high-risk BC patients, including both BRCA1/2 and non-BRCA genes. Thus, MGPT may be an effective approach to support appropriate clinical management for both patients and their relatives.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationAdultAgedBRCA1 ProteinBRCA2 ProteinEast Asian PeopleFemaleHumansJapanMiddle AgedPrevalenceBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBreast cancerGenetic testingHereditary breast and ovarian cancerJapan

Identifiers

PMID42126782
PMCPMC13283129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.